
Azilsartan tablets
Form: Tablets
Strength: 40 mg
Reference Brands: Edarbi(EU), Takarta(US)
Category: Hypertension
Azilsartan tablets, marketed as Edarbi in the EU and Takarta in the US, are approved for hypertension management. Regulatory approval requires comprehensive dossiers including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews detailed clinical trial and quality data for approval, while the EMA ensures compliance with regional safety and quality standards. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Supporting regional compliance facilitates timely approval, safe use, and global availability of azilsartan tablets, helping patients worldwide control blood pressure and reduce cardiovascular risks effectively.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Antithymocyte Globulin (ATG) powder for injection
Strength: 250mg/5ml
Form: Lyophilized powder
Reference Brands: Thymoglobulin(US & EU)
View Details Get EnquiryHydralazine tablets
Strength: 10 mg, 25 mg, 50 mg, 100 mg
Form: Tablets
Reference Brands: Apresoline(US & Eu)
View Details Get EnquiryMethyldopa tablets
Strength: 250 mg, 500 mg, and 750 mg
Form: Tablets
Reference Brands: Aldomet(US)
View Details Get EnquiryClonidine Patch
Strength: 0.1 mg/24 hours, 0.2 mg/24 hours, 0.3 mg/24 hours
Form: transdermal patch
Reference Brands: Catapres(US)
View Details Get Enquiry